Our results indicate that a strategy to interfere with the Sema7a–GPIb interaction might result in reduced cardiac damage and improved myocardial outcome following MI and should therefore be pursued as a therapeutic option in the future. The gene discussed is SEMA7A; the disease is myocardial infarction.